Primary Mitochondrial Myopathy With Muscle Weakness Therapeutics
1. Forzinity patent expiration
Treatment: Method for treating barth syndrome in adult and pediatric patients weighing at least 30kg
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7576061 | STEALTH BIOTHERAPS | Methods For Preventing Mitochondrial Permeability Transition |
Jan, 2027
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687519 | STEALTH BIOTHERAPS | Methods And Compositions For The Prevention Or Treatment Of Barth Syndrome |
Feb, 2034
(8 years from now) | |
| US12268724 | STEALTH BIOTHERAPS | Methods And Compositions For The Prevention Or Treatment Of Barth Syndrome |
Feb, 2034
(8 years from now) | |
| US11771734 | STEALTH BIOTHERAPS | Methods And Compositions For The Prevention Or Treatment Of Barth Syndrome |
Feb, 2034
(8 years from now) | |
| US11083771 | STEALTH BIOTHERAPS | Methods And Compositions For The Prevention Or Treatment Of Barth Syndrome |
Feb, 2034
(8 years from now) | |
| US11083772 | STEALTH BIOTHERAPS | Methods And Compositions For The Prevention Or Treatment Of Barth Syndrome |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2030 |
Drugs and Companies using ELAMIPRETIDE HYDROCHLORIDE ingredient
NCE-1 date: 19 September, 2029
Market Authorisation Date: 19 September, 2025
Dosage: SOLUTION
More Information on Dosage
FORZINITY family patents
